Six Vidipha executives seek to resign after nearly 34% of shares change hands
Vietnamese pharmaceutical company Vidipha disclosed on November 13, 2026, that its chairman and five other directors and supervisors had submitted resignations, subject to shareholder approval. The executives and their relatives had previously sold nearly 7.5 million shares, representing about 34% of the company’s share capital. Revenue and pre-tax profit rose year on year in the first nine months.
Vidipha Central Pharmaceutical Joint Stock Company (Vidipha, stock code VDP) disclosed on November 13, 2026, that it had received resignation letters on November 12 from six senior officials: Chairman Kiều Hữu; directors Hoàng Thế Bắc, Trần Văn Đạt and Phạm Tuấn Kiệt; Supervisory Board head Doãn Thị Ngọc Bội; and supervisor Nguyễn Quang Toản. All six cited personal reasons and said they could not devote enough time to their duties. They asked for their resignations to take effect upon approval by the shareholders’ meeting. Hoàng Thế Bắc’s letter concerns only his board position; he remains a deputy general director of the company.
If the resignations are approved, Vidipha’s board will have only three independent directors remaining: Bạch Quốc Vinh, Hà Lan Anh and Nguyễn Đức Anh. All three were elected at an extraordinary shareholders’ meeting on January 8, 2026. Nguyễn Thị Thủy will be the sole remaining member of the Supervisory Board.
Before the group submitted their resignations, these executives and their relatives had sold a combined nearly 7.5 million Vidipha shares, representing about 34% of the company’s share capital. In August 2026, Kiều Hữu and his daughter sold their entire holdings of more than 1.65 million and nearly 1.38 million shares, respectively. Trần Văn Đạt and his wife sold 899,320 and more than 1.02 million shares, respectively. Phạm Tuấn Kiệt’s wife sold more than 2.5 million shares.
Among the buyers, Lê Quang Hải now holds more than 5.03 million shares, or 15.74% of the company’s share capital; Nguyễn Quốc Hùng holds more than 4.41 million shares, or nearly 13.8%; and Nguyễn Thị Yến holds 3.83 million shares, or 11.96%. DSC Securities Joint Stock Company and Vietnam Pharmaceutical Corporation - JSC are also major shareholders, with stakes of 19.84% and 14.29%, respectively.
In the third quarter of 2026, Vidipha recorded net revenue of VND 230 billion, up 16% year on year, and after-tax profit of about VND 16 billion, up 30%. For the first nine months, cumulative net revenue was about VND 658 billion, up 4% year on year, while pre-tax profit was VND 59 billion, up nearly 6%.
Source: VietVance
